Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

46.54USD
19 Jul 2018
Change (% chg)

$-1.00 (-2.10%)
Prev Close
$47.54
Open
$47.30
Day's High
$47.73
Day's Low
$46.13
Volume
87,495
Avg. Vol
108,245
52-wk High
$52.76
52-wk Low
$12.04

Latest Key Developments (Source: Significant Developments)

G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso
Monday, 16 Apr 2018 06:00am EDT 

April 16 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL OF G1T38 IN COMBINATION WITH TAGRISSO FOR EGFR-MUTANT NON-SMALL CELL LUNG CANCER.G1 THERAPEUTICS INC - ASTRAZENECA IS PROVIDING TAGRISSO FOR PHASE 1B/2 CLINICAL TRIAL UNDER NON-EXCLUSIVE CLINICAL TRIAL COLLABORATION AGREEMENT.G1 THERAPEUTICS - OPEN-LABEL TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 145 PARTICIPANTS IN TWO PARTS.  Full Article

G1 Therapeutics Files For Offering Of 3 Mln Shares
Monday, 5 Mar 2018 04:43pm EST 

March 5 (Reuters) - G1 Therapeutics Inc ::FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK.  Full Article

G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer
Monday, 5 Mar 2018 06:00am EST 

March 5 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER.G1 THERAPEUTICS - CURRENTLY CONDUCTING TWO ADDITIONAL CLINICAL TRIALS OF TRILACICLIB WITH PRELIMINARY DATA FROM BOTH EXPECTED IN Q4 2018.G1 THERAPEUTICS - TRILACICLIB REDUCED CLINICALLY RELEVANT CONSEQUENCES OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION VERSUS PLACEBO.G1 THERAPEUTICS INC - STATISTICALLY SIGNIFICANT RESULTS FROM PHASE 2A TRIAL EVALUATING TRILACICLIB.  Full Article

G1 Therapeutics Qtrly Net Loss Per Share $0.60
Wednesday, 21 Feb 2018 04:01pm EST 

Feb 21 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS.QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.60.Q1 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.  Full Article

G1 Therapeutics qtrly ‍loss per share $0.55
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 therapeutics reports third quarter 2017 financial results and recent operational highlights.G1 therapeutics inc - qtrly ‍loss per share $0.55.G1 therapeutics inc - qtrly loss per share ‍$0.55​.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.G1 therapeutics inc- ‍cash, cash equivalents and short-term investments totaled $118.4 million as of sept 30, 2017, versus $47.3 million as of dec 31, 2016​.  Full Article

G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​.G1 Therapeutics Inc - ‍G1 announced that chief business officer Greg Mossinghoff will depart company in January of 2018​.  Full Article

G1 Therapeutics Q2 loss per share $1.09‍​
Wednesday, 9 Aug 2017 07:30am EDT 

Aug 9 (Reuters) - G1 Therapeutics Inc :G1 Therapeutics reports second quarter 2017 financial results and recent operational highlights.Qtrly loss per share $1.09‍​.Estimates that operating expenses will be in range of $55-$60 million for 2017​.  Full Article

G1 Therapeutics announces closing of initial public offering
Tuesday, 23 May 2017 08:00am EDT 

May 23 (Reuters) - G1 Therapeutics Inc :G1 Therapeutics announces closing of initial public offering.  Full Article

G1 Therapeutics shares open flat from IPO price in debut
Wednesday, 17 May 2017 10:54am EDT 

May 17 (Reuters) - :G1 Therapeutics Inc shares open at $15 in debut on the Nasdaq versus IPO price of $15 per share.  Full Article

G1 Therapeutics announces pricing of initial public offering
Tuesday, 16 May 2017 07:25pm EDT 

May 16 (Reuters) - G1 Therapeutics Inc ::G1 Therapeutics announces pricing of initial public offering.Pricing of its initial public offering of 7 million shares of common stock at a public offering price of $15.00 per share.  Full Article

BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70

* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE